Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- TBA
Speaker Profile
Ph.D., Associate Professor, UCSF
Biography
Marina is an Associate Professor at the Bakar Computational Health Sciences Institute at UCSF. Prior to that she was a Senior Research Scientist at Pfizer after getting her PhD in Biomedical Informatics at Stanford. Dr. Sirotas research experience spans over 10 years during which she has co authored over 100 scientific publications. Her research interests lie in developing computational integrative methods and applying these approaches in the context of disease diagnostics and therapeutics. The Sirota laboratory is funded by NIA, NLM, NIAMS, March of Dimes and the Burroughs Wellcome Fund. As a young leader in the field, she has been awarded the AMIA Young Investigator Award in 2017. Dr. Sirota also is the director of the AI4ALL program at UCSF, with the goal of introducing high school girls to applications of AI in biomedicine and serves as the director of outreach and advocacy at the Bakar Computational Health Sciences Institute.
